Choice Of Warp Speed Chief Rankles Consumers, Pleases Industry

By John Wilkerson / May 14, 2020 at 3:38 PM
The choice of a former drug executive to run the White House’s Operation Warp Speed divides the drug industry, which backs the appointment of GlaxoSmithKline executive Moncef Slaoui, and consumers lobbyists, who say the choice shows the administration is not serious about controlling prices for COVID-19 vaccines and drugs. Biotechnology Innovation Organization President and CEO Jim Greenwood said Slaoui is an “excellent choice” to lead the administration’s initiative to speed vaccine development and manufacturing for the United States. “Over his...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.